Atomo Diagnostics Ltd. (AU:AT1)
ASX:AT1
Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$24.33M
Enterprise ValueAU$21.57M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding901,084,350
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Integrated RDT PlatformAtomo's integrated platform combines lancet, blood collection and delivery into a single OEM device. This proprietary design creates product stickiness and a technical moat, supporting recurring B2B unit sales to diagnostic partners and durable revenue potential as partners scale.
Low Financial LeverageMinimal leverage (debt-to-equity ~0.03) reduces refinancing and solvency risk. Low debt gives management financial flexibility to fund R&D or commercial expansion during a loss-making phase, helping sustain operations and pursue partner adoption over the medium term.
Attractive Device-level Gross MarginsA near-50% gross margin indicates solid unit economics at the device/manufacturing level. With scale and tightened SG&A, these margins provide a realistic route to positive operating leverage and sustainable profitability as volume from partners increases.
Bears Say
Declining RevenueTop-line contraction reduces scale benefits and undermines per-unit economics. Falling revenue signals weaker partner adoption or program demand, limiting cash generation and constraining the firm's ability to invest in commercialization and reach manufacturing scale.
Severe Negative ProfitabilityDeep operating losses and negative returns indicate current business economics do not cover operating costs. Persistent heavy losses erode shareholder equity, increase dilution risk, and impair capacity to fund R&D or sales initiatives without external capital or a clear structural turnaround.
Worsening Cash Flow TrendsNegative operating cash flow and a sharp decline in free cash flow growth signal deteriorating cash conversion. Continued cash burn shortens runway, increases reliance on fundraising, and constrains durable investments in production scale-up and partner support.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$24.33M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Apr 28, 2026 which is today.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Atomo Diagnostics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 901,084,350 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Atomo Diagnostics Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.895%.
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AT1 Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
-58.40%
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Technical Analysis
Options Prices
Currently, No data available
---